Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Alrizomadlin |
Trade Name | |
Synonyms | APG115|APG 115|APG-115 |
Drug Descriptions |
Alrizomadlin (APG-115), a derivative of SAR405838, inhibits MDM2 and its interaction with p53, thereby stabilizing and activating wild-type p53, which may result in antitumor activity and also synergizes with PD-1 inhibitors (PMID: 28498808, PMID: 31779710). |
DrugClasses | MDM2 Inhibitor 23 |
CAS Registry Number | 1818393-16-6 |
NCIT ID | C132991 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Alrizomadlin | Alrizomadlin | 1 | 6 |
Alrizomadlin + APG-2575 | APG-2575 Alrizomadlin | 0 | 1 |
Alrizomadlin + Azacitidine | Alrizomadlin Azacitidine | 0 | 1 |
Alrizomadlin + Carboplatin | Alrizomadlin Carboplatin | 0 | 0 |
Alrizomadlin + Pembrolizumab | Alrizomadlin Pembrolizumab | 0 | 1 |